212 related articles for article (PubMed ID: 29497605)
21. Switching and withdrawing hormonal agents for castration-resistant prostate cancer.
Lorente D; Mateo J; Zafeiriou Z; Smith AD; Sandhu S; Ferraldeschi R; de Bono JS
Nat Rev Urol; 2015 Jan; 12(1):37-47. PubMed ID: 25563847
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.
Imamura Y; Sadar MD
Int J Urol; 2016 Aug; 23(8):654-65. PubMed ID: 27302572
[TBL] [Abstract][Full Text] [Related]
23. A Systematic Comparison of Antiandrogens Identifies Androgen Receptor Protein Stability as an Indicator for Treatment Response.
Siciliano T; Simons IH; Beier AK; Ebersbach C; Aksoy C; Seed RI; Stope MB; Thomas C; Erb HHH
Life (Basel); 2021 Aug; 11(9):. PubMed ID: 34575023
[TBL] [Abstract][Full Text] [Related]
24. Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance.
Tian X; He Y; Zhou J
Front Pharmacol; 2015; 6():57. PubMed ID: 25852559
[TBL] [Abstract][Full Text] [Related]
25. Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer.
Culig Z
Curr Mol Biol Rep; 2017; 3(4):230-235. PubMed ID: 29214142
[TBL] [Abstract][Full Text] [Related]
26. Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair.
Elsesy ME; Oh-Hohenhorst SJ; Löser A; Oing C; Mutiara S; Köcher S; Meien S; Zielinski A; Burdak-Rothkamm S; Tilki D; Huland H; Schwarz R; Petersen C; Bokemeyer C; Rothkamm K; Mansour WY
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32878283
[TBL] [Abstract][Full Text] [Related]
27. Discovery and Identification of Pyrazolopyramidine Analogs as Novel Potent Androgen Receptor Antagonists.
Wang L; Song T; Wang X; Li J
Front Pharmacol; 2018; 9():864. PubMed ID: 30210333
[TBL] [Abstract][Full Text] [Related]
28. Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same?
Yekedüz E; Utkan G; Kanesvaran R; Ürün Y
Prostate Int; 2021 Mar; 9(1):1-5. PubMed ID: 33912507
[TBL] [Abstract][Full Text] [Related]
29. Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance.
Salami J; Alabi S; Willard RR; Vitale NJ; Wang J; Dong H; Jin M; McDonnell DP; Crew AP; Neklesa TK; Crews CM
Commun Biol; 2018; 1():100. PubMed ID: 30271980
[TBL] [Abstract][Full Text] [Related]
30. Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies.
Obst JK; Wang J; Jian K; Williams DE; Tien AH; Mawji N; Tam T; Yang YC; Andersen RJ; Chi KN; Montgomery B; Sadar MD
ACS Pharmacol Transl Sci; 2019 Dec; 2(6):453-467. PubMed ID: 32259077
[TBL] [Abstract][Full Text] [Related]
31. Androgen Receptor Signaling Inhibition in Advanced Castration Resistance Prostate Cancer: What Is Expected for the Near Future?
Pozas J; Álvarez Rodríguez S; Fernández VA; Burgos J; Santoni M; Manneh Kopp R; Molina-Cerrillo J; Alonso-Gordoa T
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551557
[TBL] [Abstract][Full Text] [Related]
32. Nonsteroidal androgen receptor ligands: versatile syntheses and biological data.
Varchi G; Guerrini A; Tesei A; Brigliadori G; Bertucci C; Di Donato M; Castoria G
ACS Med Chem Lett; 2012 Jun; 3(6):454-8. PubMed ID: 24900495
[TBL] [Abstract][Full Text] [Related]
33. Grappling with the androgen receptor: a new approach for treating advanced prostate cancer.
Thompson TC
Cancer Cell; 2010 Jun; 17(6):525-6. PubMed ID: 20541694
[TBL] [Abstract][Full Text] [Related]
34. Reversing resistance to antiandrogens with a histone deacetylase inhibitor.
Ferrari AC
Oncotarget; 2018 Dec; 9(99):37284-37285. PubMed ID: 30647867
[No Abstract] [Full Text] [Related]
35. Second-line therapy in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel: A systematic review of nine randomized controlled trials.
Poorthuis MHF; Vernooij RWM; van Moorselaar RJA; de Reijke TM
Semin Oncol; 2017 Oct; 44(5):358-371. PubMed ID: 29580437
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of different interventions in castration resistant prostate cancer progressing after docetaxel-based chemotherapy: Bayesian network analysis of randomized controlled trials.
Zhao Y; Huang H; Chen C; Liu H; Liu H; Su F; Bi J; Lam TB; Li J; Lin T; Huang J
J Cancer; 2018; 9(4):690-701. PubMed ID: 29556327
[No Abstract] [Full Text] [Related]
37. Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade.
Nagai T; Naiki T; Iida K; Etani T; Ando R; Hamamoto S; Sugiyama Y; Akita H; Kubota H; Hashimoto Y; Kawai N; Yasui T
Prostate Int; 2018 Mar; 6(1):18-23. PubMed ID: 29556485
[TBL] [Abstract][Full Text] [Related]
38. Profiling Prostate Cancer Therapeutic Resistance.
Wade CA; Kyprianou N
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562686
[TBL] [Abstract][Full Text] [Related]
39. Estrogen therapy in patients with prostate cancer: a contemporary systematic review.
Reis LO; Zani EL; García-Perdomo HA
Int Urol Nephrol; 2018 Jun; 50(6):993-1003. PubMed ID: 29600433
[TBL] [Abstract][Full Text] [Related]
40. Influence of prior oral ethinylestradiol use on the efficacy of enzalutamide for the treatment of castration-resistant prostate cancer in men.
Hakariya T; Shida Y; Tsurusaki T; Watanabe J; Furukawa M; Matsuya F; Miyata Y; Sakai H
Int J Urol; 2018 May; 25(5):464-470. PubMed ID: 29521011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
